In addition to the mutations mentioned above, we also found CH mutations in genes playing important roles in cancer therapy, such as FGFR3, EGFR, PTEN, ERBB2 and TP53, indicating the importance of correctly managing CH mutations when making clinical decisions based on liquid biopsy. The gene discussed is ERBB2; the disease is cancer.